Benj Garrett
Partner
New York Office | benj.garrett@torreya.com | 212.257.5807
Benj Garrett, Partner, has been lead banker on well over a billion dollars of transactions while at Torreya, generating substantial amounts of the firm’s total revenue over multiple years. He joined the firm in 2008 and was made the youngest Managing Director.
His experience crosses a wide spectrum in the life sciences, having led transactions as early as preclinical biotech, clinical stage, commercial stage and generics. Over a number of years, he has been successful in both origination and execution roles.
His experience covers cross-border transactions from both Japanese and Indian pharmaceutical companies. Recent notable transactions on which Benj has worked include Santen acquisition of Eyevance, Avenue Therapeutics sale to Cipla, Tris debt recapitalization and the acquisition of NextWave Pharmaceuticals from Pfizer, and Sawai acquisition of the generics business of Upsher-Smith.
Benj graduated summa cum laude from NYU’s Stern School of Business, with a B.S. in finance and statistics.
Selected Transactions
|
| Acquired by |
|
|
August 2021
|
|
| Acquisition of |
|
|
$225 million
September 2020
|
|
| Sale of stock and conditional sale to |
|
|
$215 million + CVRs
February 2019
|
|
| Debt recapitalization and acquisition of NextWave Pharmaceuticals from |
|
|
$125 million
September 2018
|
|
| Acquisition of generics business of |
|
|
$1.05 billion
June 2017
|
|
| Acquired by |
|
|
August 2022
|
|
| Venture debt raise with |
|
|
$20 million
April 2019
|
|
| Sale of Sevelamer ANDA to |
|
|
October 2018
|
|
|
| Sale of ANDA portfolio to |
|
|
January 2018
|
|
|
| Sale of generics portfolio to |
|
|
$18 million
August 2017
|
|
| Sale of royalties to |
|
|
$22 million
December 2016
|
|
| Partial sale of royalty and milestones |
|
|
$40 million
September 2016
|
|
| Sale of phase II enzyme replacement royalty |
|
|
|
August 2016
|
|
| Sale and contribution of orphan disease asset to |
|
|
May 2016
|
|
| Sale of Akarx to |
|
|
March 2016
|
|
|
| Sale of Zonalon® to |
|
|
March 2015
|
|
| Sale of Pessac plant to |
|
|
Up to €22 million
November 2014
|
|
|
| Divestiture of certain abbreviated new drug applications to |
|
|
Up to $18 million
October 2014
|
|
| Acquisition of Donnatal® from |
|
|
$328 million
May 2014
|
|
| Sale of 31 abbreviated new drug applications to |
|
|
$12.5 million +
profit share December 2013
|
|
| Sale to |
|
|
|
December 2013
|
|
| Sale to |
|
|
19.9% of shares +
$12 million November 2013
|
|
| Sale of Naprelan® to |
|
|
November 2013
|
|
|
| Divestiture of three pediatric drugs to |
|
|
|
$28.7 million
May 2013
|
|
| Sale of Fareston® to |
|
|
$21.7 million
October 2012
|
|
|
| Divestiture of Cuvposa® to |
|
|
August 2012
|
|
| Sale of dermatology specialty pharma business to |
|
|
December 2010
|
|
| Sale to |
|
|
$100+ million
October 2010
|
|
| Advisor in the acquisition of six products from |
|
|
July 2010
|
|
| Sale of Crinone® & Prochieve® product lines and shares to |
|
|
$92.5 million with
$47 million upfront July 2010
|
|
| Advisor to Genentech major shareholder in sale to |
|
|
$46 billion
March 2009
|